Titre :

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT.

Auteur(s) :

Drozd-Sokołowska, J. [Auteur]
Gras, L. [Auteur]
Zinger, N. [Auteur]
Snowden, J. A. [Auteur]
Arat, M. [Auteur]
Basak, G. [Auteur]
Pouli, A. [Auteur]
Crawley, C. [Auteur]
Wilson, K. M. O. [Auteur]
Tilly, Hervé [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Byrne, J. [Auteur]
Bulabois, Claude E. [Auteur]
Université Grenoble Alpes [UGA]
Passweg, J. [Auteur]
Ozkurt, Z. N. [Auteur]
Schroyens, W. [Auteur]
Lioure, Bruno [Auteur]
Colorado Araujo, M. [Auteur]
Poiré, X. [Auteur]
Van Gorkom, G. [Auteur]
Gurman, G. [Auteur]
De Wreede, L. C. [Auteur]
Hayden, P. J. [Auteur]
Beksac, M. [Auteur]
Schönland, S. O. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Numéro :

57

Pagination :

633–640

Date de publication :

2022-02-18

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is ...
Lire la suite >Autologous hematopoietic cell transplantation (auto-HCT) may be performed in multiple myeloma (MM) patients relapsing after a previous auto-HCT. For those without an adequate dose of stored stem cells, remobilization is necessary. This retrospective study included patients who, following disease relapse after the first auto-HCT(s), underwent stem cell remobilization and auto-HCT performed using these cells. There were 305 patients, 68% male, median age at salvage auto-HCT was 59 years. The median time to relapse after the first-line penultimate auto-HCT(s) was 30.6 months, the median follow-up after salvage auto-HCT 31 months. The 2- and 4-year non-relapse mortality (NRM) after the salvage auto-HCT was 5 and 9%, the relapse incidence 56 and 76%, respectively. Overall survival (OS) after 2 and 4 years was 76 and 52%, progression-free survival (PFS) 39 and 15%. In multivariable analysis an increasing interval between the penultimate auto-HCT and relapse was associated with better OS and PFS, later calendar year of salvage auto-HCT with better OS. In conclusion, salvage auto-HCT performed with cells remobilized after a previous auto-HCT was associated with acceptable NRM. The leading cause of failure was disease progression of MM, which correlated with a shorter interval from the penultimate auto-HCT to the first relapse.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T02:16:00Z
2024-03-25T10:19:45Z